Status:
COMPLETED
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic bre...
Eligibility Criteria
Inclusion
- female patients, \>=18 years of age;
- metastatic breast cancer;
- HER2 overexpression (IHC 3+ and/or FISH positive);
- disease progression during or after previous 1st line chemotherapy plus Herceptin;
- scheduled to receive 2nd line chemotherapy.
Exclusion
- incompatibility with previous Herceptin therapy;
- pregnancy.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00448279
Start Date
April 1 2007
End Date
September 1 2010
Last Update
October 24 2014
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Avellino, Italy, 83100
2
Brescia, Italy, 25123
3
Candiolo, Italy, 10060
4
Carrara, Italy, 54033